Login to Your Account

Ovid, Takeda to carry drug for rare pediatric epilepsies forward

By Michael Fitzhugh
Staff Writer

Wednesday, January 18, 2017

Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics Inc. have agreed to jointly develop and commercialize Takeda's TAK-935 in rare pediatric epilepsies, splitting costs and potential profits 50-50.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription